|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2010-7-15
|
|
pubmed:abstractText |
We conducted a phase I trial of the topoisomerase I inhibitor topotecan for the purpose of determining the maximum tolerated dose (MTD) and the dose-limiting toxicities (DLTs) of topotecan when administered weekly to patients with advanced non-small-cell lung cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1938-0690
|
|
pubmed:author |
pubmed-author:AraseHiroakiH,
pubmed-author:FukuokaMasahiroM,
pubmed-author:IjimaToshiyukiT,
pubmed-author:KudohShinzohS,
pubmed-author:MasudaNoriyukiN,
pubmed-author:MatsuiKaoruK,
pubmed-author:MukaiyamaAkihiraA,
pubmed-author:NakagawaKazuhikoK,
pubmed-author:NegoroShunichiS,
pubmed-author:TakadaMinoruM,
pubmed-author:TakedaKojiK,
pubmed-author:YoshidaPascalP
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
11
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
271-9
|
|
pubmed:meshHeading |
pubmed-meshheading:20630830-Adenocarcinoma,
pubmed-meshheading:20630830-Aged,
pubmed-meshheading:20630830-Antineoplastic Agents,
pubmed-meshheading:20630830-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:20630830-Carcinoma, Squamous Cell,
pubmed-meshheading:20630830-Drug Resistance, Neoplasm,
pubmed-meshheading:20630830-Female,
pubmed-meshheading:20630830-Humans,
pubmed-meshheading:20630830-Lung Neoplasms,
pubmed-meshheading:20630830-Male,
pubmed-meshheading:20630830-Maximum Tolerated Dose,
pubmed-meshheading:20630830-Middle Aged,
pubmed-meshheading:20630830-Salvage Therapy,
pubmed-meshheading:20630830-Survival Rate,
pubmed-meshheading:20630830-Tissue Distribution,
pubmed-meshheading:20630830-Topotecan,
pubmed-meshheading:20630830-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Phase I and pharmacologic study of weekly bolus topotecan for advanced non-small-cell lung cancer.
|
|
pubmed:affiliation |
Department of Respiratory Medicine, Kitasato University School of Medicine, Japan. masuda@med.kitasato-u.ac.jp
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial, Phase I
|
